Antares Pharma Inc
Makena Auto Injector Is a Key Asset for Antares Pharma in 2018
In H1 2018, Antares Pharma (ATRS) reported revenues of $6.7 million from its Makena product.
Antares Pharma Is Expected to Report Positive EPS in 2019
In H1 2018, Antares Pharma (ATRS) reported a loss per share of $0.07, which was higher by $0.02 on a year-over-year (or YoY) basis.
Antares Pharma Could Report Solid Revenue Growth in Fiscal 2018
In H1 2018, Antares Pharma (ATRS) reported revenues of $26.86 million, which was a year-over-year (or YoY) rise of 6%.
Here’s Why Antares Pharma Stock Rose on October 2
Antares Pharma (ATRS) rose a solid 15.64% from $3.26 on October 1 to $3.77 on October 2.
Label Expansion of Ferahame Bodes Well for AMAG Pharmaceuticals
AMAG’s revenues from Ferahame grew at a higher pace to $26 million in 3Q17 from $22.2 million in 3Q16.
Antares Pharma’s Sale of ZomaJet to Ferring Pharmaceuticals
ZomaJet is Antares Pharma’s needle-free autoinjector, which is designed to deliver human growth hormone (or HGH) treatment to children with growth retardation.
Exploring Antares Pharma’s Current Pipeline of Products
On October 11, 2017, Antares Pharma (ATRS) was notified by the FDA that it had found deficiencies in Xyosted.
Which Products Are Driving Revenues for Antares Pharma in 2017?
Sumatriptan is the only injectable triptan approved for use in the US. The product achieved a market share of 26.0% in 2Q17, up from 21.0% in 1Q17.
Analysts’ Recommendations for Antares Pharma in November 2017
Antares Pharma’s (ATRS) products include Vibex, a pressure-assisted autoinjector. The global injectable drug delivery market is expected to grow to $624.5 billion by 2021.